SESH INCORPORATED
San Diego, CA
What changed
NIH U43 · $0.4M · HLA LOH Detection via Liquid Biopsy: A Blood-Based Predictive Biomarker Assay for Precision Immuno-Oncology
10mo agoNew grantSep 11, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 31 out of 100, unchanged since the last recompute.
Little recent filing activity, or the events on file have decayed.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Grant-only
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Grant
U43 · $407k · non-dilutive
Sep 12, 2025SESH INCORPORATED · PI SINKOE, ANDREW · NCI · award ends Aug 31, 2027 · HLA LOH Detection via Liquid Biopsy: A Blood-Based Predictive Biomarker Assay for Precision Immuno-Oncology
NIH RePORTER · NIH RePORTER 11254232 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources